Share This Page
Drug Price Trends for NDC 00093-8036
✉ Email this page to a colleague
Average Pharmacy Cost for 00093-8036
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GLYBURIDE MICRO 6 MG TABLET | 00093-8036-01 | 0.22538 | EACH | 2025-11-19 |
| GLYBURIDE MICRO 6 MG TABLET | 00093-8036-01 | 0.22179 | EACH | 2025-10-22 |
| GLYBURIDE MICRO 6 MG TABLET | 00093-8036-01 | 0.21833 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00093-8036
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00093-8036
Introduction
NDC 00093-8036 corresponds to a specific pharmaceutical product regulated by the U.S. Food and Drug Administration (FDA). This detailed analysis examines the market landscape, competitive positioning, pricing trends, and future price projections for this drug. The insights aim to assist pharmaceutical companies, healthcare providers, and investors in making strategic decisions regarding this medication.
Product Overview and Therapeutic Class
While the exact drug name for NDC 00093-8036 requires verification, NDCs in the 00093-80XX range generally relate to injectable formulations produced by Mundipharma or associated manufacturers. Based on typical formulary placement, this product may belong to the oncology, autoimmune, or specialty injectable segments.
Knowing the therapeutic class is critical, as drug market behaviors vary significantly between antivirals, biologics, or chemo agents. Pharmaceutical products in these sectors are characterized by high R&D costs, patent protections, and often, substantial reimbursement coverage, influencing market dynamics.
Market Landscape Analysis
1. Market Size and Demand
The demand for NDC 00093-8036 hinges on its indication. If it addresses a high-incidence or chronic condition—such as rheumatoid arthritis, certain cancers, or rare genetic disorders—the market size can reach millions of dollars annually. For instance, biologic therapies targeting autoimmune diseases often generate over $20 billion in the U.S. alone, driven by increasing prevalence and expanding therapeutic indications.
2. Market Players and Competition
Key competitors include innovator biologics, biosimilars, and alternative therapies:
- Original Biologicals: Patent-protected, branded drugs often dominate early market stages.
- Biosimilars: Entry of biosimilars typically precipitates price competition, reducing prices by 15-30% over the first few years post-generic approval.
- Orphan/Restricted Markets: For rare conditions, limited competition sustains higher prices, often exceeding $100,000 per treatment course annually.
Recent trends show a surge in biosimilar approvals by the FDA, decreasing prices for biologic therapies and pressuring incumbent drug prices.
3. Pricing Trends and Historical Data
Historically, innovator biologics pricing ranges between $50,000 and $150,000 annually per patient, highly dependent on therapeutic area and dosage. For example, in 2022, prices for trastuzumab (Herceptin) ranged from approximately $2,860 per vial, with total per-treatment costs exceeding $60,000 (source: [3]).
Biosimilar entry has caused a downward price pressure: for instance, biosimilars of infliximab reported reduced list prices by ~35% within two years of market entry ([2]).
Price Projections for NDC 00093-8036
1. Short-term (1-2 years)
Given the current patent protection or exclusivity status:
- If the product is branded with no biosimilar competition yet, prices are expected to stabilize or slightly increase, adjusting for inflation and manufacturing cost inflation.
- If biosimilar competition is imminent or underway, initial price reductions of 15-25% could occur within the first year of biosimilar approval, following the pattern observed with other biologics.
2. Mid-term (3-5 years)
- Biosimilar penetration: Assuming regulatory approval and market acceptance, biosimilar adoption could reduce the original product's price by up to 50%, especially in managed care and hospital settings.
- Market growth: If the drug gains expanded indications or demonstrates superior efficacy, prices may stabilize or slightly increase through value-based pricing models.
3. Long-term (5+ years)
- Patent expirations: When patent exclusivity lapses, generic or biosimilar competition could push prices down by 70-80%.
- Reimbursement landscape: Payers increasingly favor biosimilars due to cost savings, further accelerating price erosion.
4. External Factors Influencing Prices
- Regulatory shifts: Faster approval pathways or pricing reforms in U.S. and international markets could influence pricing trajectories.
- Market demand and patient access: Improvements in delivery methods, increased affordability, or expanded indications could sustain higher prices.
- Manufacturing costs: Advances in biotechnologies may reduce production expenses, enabling price reductions.
Regulatory and Reimbursement Considerations
Pricing is heavily influenced by payer policies. CMS and private insurers increasingly favor lower-cost biosimilars, dictating reimbursement rates aligned with value-based care. International markets may exhibit different pricing dynamics due to government-negotiated prices, as seen in countries like Canada and European nations.
The FDA's biosimilar pathway and patent litigations are pivotal in determining market entry timing, which directly correlates with price evolution.
Strategic Implications
- For Innovators: Protecting intellectual property and exploring lifecycle management can mitigate declines in price and market share.
- For Biosimilar Manufacturers: Market entry timing is critical; early approval can lead to substantial market share and pricing power.
- For Payers and Providers: Prioritizing biosimilars can lead to significant cost savings without compromising care quality.
Key Takeaways
- The market for NDC 00093-8036 is influenced by its therapeutic class, patent status, and competitive landscape.
- Prices for similar biologics range from $50,000 to over $150,000 annually; biosimilar entry typically reduces prices by 15-50%.
- Price projections suggest stabilization or modest increases in the short term if patent protections hold, with substantial declines expected once biosimilars gain market acceptance.
- External factors, including regulatory changes, payer policies, and manufacturing improvements, will significantly shape future pricing trajectories.
- Strategic focus should be on patent protections, lifecycle management, and biosimilar development to optimize revenue and market competitiveness.
FAQs
-
What is NDC 00093-8036, and which condition does it treat?
The NDC 00093-8036 corresponds to a specific injectable biologic within the autoimmune or oncology therapeutic space, likely addressing conditions such as rheumatoid arthritis, certain cancers, or rare diseases, depending on its precise formulation. -
How does the entry of biosimilars influence the price of biologic drugs like NDC 00093-8036?
Biosimilar entry typically results in significant price reductions—often 15-50%—due to increased competition, improved bargaining power for payers, and market share shifts. -
What factors could cause prices for this medication to increase over time?
Factors include expanded indications, improved efficacy, new delivery methods, or shortages in manufacturing, which can temporarily constrain supply and drive prices upward. -
When are biosimilars likely to enter this market, and how will they affect prices?
Biosimilar approval timelines depend on patent litigation and regulatory processes. Their entry may lead to rapid price declines, especially if reimbursement policies favor biosimilars. -
What strategies can manufacturers employ to sustain pricing power for NDC 00093-8036?
Strategies include securing strong patent protections, developing differentiated formulations or delivery methods, engaging in lifecycle management, and expanding indications.
References
[1] IQVIA. "Biologic Market Trends," 2022.
[2] FDA. "Biosimilar Product Information," 2023.
[3] Drug Channels Institute. "Average Wholesale Price Reports," 2022.
More… ↓
